Moleculin Biotech, Inc.
MBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 21.68 | -0.36 | 1.18 |
| FCF Yield | -16.32% | -3.81% | -3.66% | -1.52% |
| EV / EBITDA | -5.38 | -20.78 | -23.45 | -51.70 |
| Quality | ||||
| ROIC | -227.97% | -94.06% | -58.12% | -28.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.10 | 0.81 | 0.95 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 1.44% | 12.56% | -46.05% | -4.54% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 0.78 | 1.40 | 3.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |